Business Context and Reporting Period
Company: Impact BioMedical, Inc. (IBO)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2026
Business Overview: The Company discovers, patents, and licenses biopharmaceutical and wellness technologies, including oncology (Linebacker), metabolic health (Laetose), functional fragrances (3F), and antiviral supplements (Equivir). It also recently acquired the Celios air purification system. The Company is classified as a smaller reporting company and an emerging growth company.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenue | $7,000 | $0 |
| Net Loss | $(2,284,000) | $(1,278,000) |
| Net Loss Attributable to Common Stockholders | $(2,287,000) | $(1,267,000) |
| Operating Cash Flow | $(464,000) | $(682,000) |
| Cash and Cash Equivalents (End of Period) | $20,000 | $1,318,000 |
| Total Assets | $17,086,000 | $17,405,000 |
| Total Liabilities | $2,375,000 | $1,850,000 |
| Stockholders' Equity | $14,711,000 | $15,555,000 |
Key Expense Drivers: Stock-based compensation was $1,440,000 in Q1 2026 compared to $2,000 in Q1 2025. Total operating expenses were $2,296,000.
Material Changes vs. Prior Period
- Revenue: Generated $7,000 in biotech retail sales (Celios air purification) in Q1 2026, compared to zero in Q1 2025.
- Net Loss: Increased by 79% to $2.28 million, primarily driven by a $1.44 million non-cash stock-based compensation charge issued to executives and board members in January 2026.
- Liquidity: Cash balances decreased significantly from $1.32 million in Q1 2025 to $20,000 in Q1 2026. The Company offset operating cash burn with $482,000 in borrowings from a related party (DSS).
- Debt: Interest expense dropped to zero in Q1 2026 after a related-party note was converted to equity in October 2025. However, "Due to related party" liabilities increased from $621,000 to $1,103,000 due to new funding advances.
- Equity: Issued 3.2 million shares of common stock in Q1 2026 as compensation, increasing total shares outstanding to 107.8 million.
Outlook, Risks, and Management Commentary
- Going Concern: The filing explicitly states that substantial doubt exists regarding the Company's ability to continue as a going concern within one year due to recurring operating losses and negative cash flows. Management plans to address this through capital raises, debt financing, and monetization of intellectual property.
- Guidance: No specific financial guidance or revenue projections were provided for the remainder of 2026.
- Operational Focus: Management is focusing on cost control, specifically reducing travel, marketing, and R&D spending. R&D expenses decreased 55% year-over-year.
- Risks:
- Reliance on related party (DSS) for funding and administrative support.
- Dependence on licensing partners (e.g., ProPhase Laboratories, Chemia) for future milestone and royalty payments, which are not guaranteed.
- Material weaknesses in internal controls over financial reporting remain unremediated as of March 31, 2026.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $20,000 cash balance against current burn rates and the reliability of related-party funding.
- Stock-Based Compensation: Confirm the valuation methodology for the $1.44 million stock grant issued in Q1 2026 and its impact on future dilution.
- Related Party Transactions: Review the terms of the $1.1 million "Due to related party" balance and the $482,000 new borrowing to understand repayment obligations and potential conversion terms.
- Revenue Sustainability: Assess the scalability of the $7,000 Celios retail revenue and the status of licensing deals with ProPhase and Chemia.
- Internal Controls: Review the status of remediation efforts for the disclosed material weaknesses in financial reporting controls.